- Home
- MRKR vs RLMD Comparison
MRKR vs RLMD Comparison
Compare MRKR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- RLMD
- Stock Information
- Founded
- MRKR N/A
- RLMD 2004
- Country
- MRKR United States
- RLMD United States
- Employees
- MRKR N/A
- RLMD N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- RLMD Health Care
- Exchange
- MRKR Nasdaq
- RLMD Nasdaq
- Market Cap
- MRKR 19.1M
- RLMD 22.0M
- IPO Year
- MRKR N/A
- RLMD N/A
- Fundamental
- Price
- MRKR $1.47
- RLMD $0.67
- Analyst Decision
- MRKR Strong Buy
- RLMD Buy
- Analyst Count
- MRKR 3
- RLMD 3
- Target Price
- MRKR $13.17
- RLMD $5.00
- AVG Volume (30 Days)
- MRKR 231.4K
- RLMD 478.7K
- Earning Date
- MRKR 08-13-2025
- RLMD 08-06-2025
- Dividend Yield
- MRKR N/A
- RLMD N/A
- EPS Growth
- MRKR N/A
- RLMD N/A
- EPS
- MRKR N/A
- RLMD N/A
- Revenue
- MRKR $5,696,123.00
- RLMD N/A
- Revenue This Year
- MRKR N/A
- RLMD N/A
- Revenue Next Year
- MRKR $11.28
- RLMD N/A
- P/E Ratio
- MRKR N/A
- RLMD N/A
- Revenue Growth
- MRKR 71.53
- RLMD N/A
- 52 Week Low
- MRKR $0.95
- RLMD $0.24
- 52 Week High
- MRKR $5.99
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- MRKR 50.81
- RLMD 52.84
- Support Level
- MRKR $1.41
- RLMD $0.67
- Resistance Level
- MRKR $1.53
- RLMD $0.72
- Average True Range (ATR)
- MRKR 0.16
- RLMD 0.08
- MACD
- MRKR -0.03
- RLMD -0.03
- Stochastic Oscillator
- MRKR 9.43
- RLMD 40.29
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.